Does Seerave have a geographic focus area?

No.


Continue Reading

Related Articles

Who have you previously partnered with?

Some of the project where we work with other philanthropic donors include:

  • PTFI
  • MDA project
  • The Microbiota Vault

Continue Reading

Related Articles

Do you jointly fund projects with other philanthropic entities?

Yes, we consider collaborations amongst philanthropic entities.


Continue Reading

Related Articles

Does the Seerave Foundation identify with or exclusively support a particular political point of view or party?

No. We support efforts that achieve our goals without regard to political affiliation.


Continue Reading

Related Articles

Where does the Seerave Foundations’ funding come from?

The funding comes from a family endowment. David Rees co-founded the downstream oil company Greenergy, which was sold in May 2017 and the resulting proceeds were bequeathed to Seerave to fund its philanthropic activities.


Continue Reading

Related Articles

Is the Seerave Foundation a non-profit organisation?

Yes. We are a registered NPO under Non-Profit Organisations (Jersey) Law 2008, with registration number NPO-7095.


Continue Reading

Related Articles

Where is the Seerave Foundation based?

The Seerave Foundation was incorporated in Jersey on 26 March 2015 as a foundation under the Foundations (Jersey) Law, 2009, as amended, with registration number FD280. Our team on the ground can be based anywhere on the globe and is arranged virtually.


Continue Reading

Related Articles

What does the Seerave Foundation do?

Seerave uses a combination of traditional grant donations towards academic researchers as well as equity investments into early-stage start-ups. Our project portfolio is built around international alliances of world-leading institutions, visionary scientists and entrepreneurs.


Continue Reading

Related Articles

What is the Seerave Foundation?

We are an active and innovative family foundation. We are inspired by personal experiences and driven by the conviction that through collaboration we will be able to accelerate science and catalyse innovation to enable personalised cancer treatment.


Continue Reading

Related Articles